Sotorasib
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.
‘Monumental’ and ‘highly meaningful’ advances across solid tumors highlight ESMO program
MADRID — Remarkable. Highly meaningful. Monumental.
Higher sotorasib dose reduces risk for death in KRAS-mutant lung cancer
A 960 mg daily dose of sotorasib conferred a longer OS benefit among certain patients with KRAS G12C-mutant advanced non-small cell lung cancer, results from a randomized phase 2 showed.
Combination superior to standard care for metastatic colorectal cancer
MADRID — Sotorasib plus panitumumab prolonged PFS compared with standard of care for patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, study results presented at ESMO Congress showed.
FDA panel: Benefit of ‘highly anticipated’ lung cancer drug can’t be interpreted reliably
An FDA advisory committee voted 10-2 that the results of a confirmatory trial for the targeted lung cancer drug sotorasib cannot be interpreted reliably.
Recent developments driving the 'evolution' of lung cancer treatments
2022 has brought many research updates and approvals in lung cancer.
Sotorasib delays progression of advanced KRAS-mutant non-small cell lung cancer
Sotorasib significantly extended PFS compared with standard-of-care docetaxel as second-line therapy for patients with KRASG12C-mutated non-small cell lung cancer, data from the randomized phase 3 CodeBreak 200 trial showed.
Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of September 12, 2022
In this edition, germline testing ‘should be considered’ for all patients with lung cancer; phase 3 trial of canakinumab misses endpoint; sexual dysfunction common among women with lung cancer, and more.
VIDEO: ‘Good research’ at lung cancer conference ‘answers some questions,’ creates others
In this video, Hossein Borghaei, DO, MS, discusses safety, response and survival data of patients with small cell lung cancer who received tarlatamab, a half-life extended bispecific T-cell engager, or HLE BiTE.
Sotorasib extends PFS in lung cancer subset
Sotorasib prolonged PFS compared with standard chemotherapy for certain patients with non-small cell lung cancer, according to topline data released by the agent’s manufacturer.